Cross-talk between toll-like receptor 4 (TLR4) and proteinase-activated receptor 2 (PAR2) is involved in vascular function

British Journal of Pharmacology

Volumn 168, Issue 2, 2013, Pages 411-420

  Bucci, M ^a   Vellecco, V ^a   Harrington, L ^b   Brancaleone, V ^a,e   Roviezzo, F ^a   Mattace Raso, G ^a   Ianaro, A ^a   Lungarella, G ^c   De Palma, R ^d   Meli, R ^a   Cirino, Giuseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF SIENA   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e UNIVERSITY OF BASILICATA   (Italy)

Author keywords

hypotension; PAR2; TLR4; vasodilatation

Indexed keywords

CURCUMIN; PROTEINASE ACTIVATED RECEPTOR 2; RESVERATROL; TOLL LIKE RECEPTOR 4;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; BLOOD VESSEL FUNCTION; CONTROLLED STUDY; ENDOTOXEMIA; ENZYME ACTIVATION; EX VIVO STUDY; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VASCULAR RING; VASODILATATION;

ANIMALS; AORTA, THORACIC; HYPOTENSION; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OLIGOPEPTIDES; RATS; RATS, WISTAR; RECEPTOR, PAR-2; TOLL-LIKE RECEPTOR 4; VASODILATION;

EID: 84871539770     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02205.x     Document Type: Article

References (52)

1. Aderem A, Ulevitch R, (2000). Toll-like receptors in the induction of the innate immune response. Nature 406: 782-787.
2. Akira S, Hemmi H, (2003). Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 85: 85-95.
3. Akira S, Uematsu S, Takeuch O, (2006). Pathogen recognition and innate immunity. Cell 124: 783-801.
4. Barton GM, Medzhitov R, (2004). Toll signalling: RIPping off the TNF pathway. Nat Immunol 5: 472-474.
5. Bengmark S, (2006). Curcumin, an atoxic antioxidant and natural NFkB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. JPEN J Parenter Enteral Nutr 30: 45-51.
6. Bucci M, Roviezzo F, Cirino G, (2005). Protease-activated receptor-2 (PAR2) in cardiovascular system. Vascul Pharmacol 43: 247-253.
7. Chung WO, An JY, Yin L, Hacker BM, Rohani MG, Dommisch H, et al,. (2010). Interplay of protease-activated receptors and NOD pattern recognition receptors in epithelial innate immune responses to bacteria. Immunol Lett 131: 113-119.
8. Cicala C, (2002). Protease activated receptor 2 and the cardiovascular system. Br J Pharmacol 135: 14-20.
9. Cicala C, Pinto A, Bucci M, Sorrentino R, Walker B, Harriot P, et al,. (1999). Protease-activated receptor-2 involvement in hypotension in normal and endotoxemic rats in vivo. Circulation 99: 2590-2597.
10. Cicala C, Morello S, Santagada V, Caliendo G, Sorrentino L, Cirino G, (2001). Pharmacological dissection of vascular effects caused by activation of protease-activated receptors 1 and 2 in anesthetized rats. FASEB J 15: 1433-1435.
11. Cottrell GS, Amadesi S, Schmidlin F, Bunnett N, (2003). Protease-activated receptor 2: activation, signalling and function. Biochem Soc Trans 31: 1191-1197.
12. Dery O, Corvera CU, Steinhoff M, Bunnett NW, (1998). Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol 274: C1429-C1452.
13. Ferrell WR, Lockhart JC, Kelso EB, Dunning L, Plevin R, Meek SE, et al,. (2003). Essential role for proteinase-activated receptor-2 in arthritis. J Clin Invest 11: 35-41.
14. Fiorucci S, Mencarelli A, Palazzetti B, Distrutti E, Vergnolle N, Hollenberg MD, et al,. (2001). Proteinase-activated receptor 2 is an anti-inflammatory signal for colonic lamina propria lymphocytes in a mouse model of colitis. Proc Natl Acad Sci U S A 98: 13936-13941.
15. Fox MT, Harriot P, Walker B, Stone SR, (1997). Identification of potential activators of proteinase activated receptor 2. FEBS Lett 417: 267-269.
16. Gruber BL, Marchese MJ, Santiago-Schwarz F, Martin CA, Zhang J, Kew RR, (2004). Protease-activated receptor-2 (PAR-2) expression in human fibroblasts is regulated by growth factors and extracellular matrix. J Invest Dermatol 123: 832-839.
17. Hansen KK, Sherman PM, Cellars L, Andrade-Gordon P, Pan Z, Baruch A, et al,. (2005). A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis. Proc Natl Acad Sci U S A 102: 8363-8368.
18. Hoffmann JA, Reichhart JM, (2002). Drosophila innate immunity: an evolutionary perspective. Nat Immunol 3: 121-126.
19. Hollenberg MD, (1999). Protease-activated receptors: PAR4 and counting: how long is the course? Trends Pharmacol Sci 20: 271-273.
20. Hollenberg MD, Compton SJ, (2002). International Union of Pharmacology XXVIII Proteinase-activated receptors. Pharmacol Rev 54: 203-217.
21. Holzhausen M, Spolidorio LC, Ellen RP, Jobin MC, Steinhoff M, Andrade-Gordon P, et al,. (2006). Protease-activated receptor-2 activation: a major role in the pathogenesis of Porphyromonas gingivalis infection. Am J Pathol 168: 1189-1199.
22. Hyun E, Andrade-Gordon P, Steinhoff M, Vergnolle N, (2008). Protease-activated receptor-2 activation: a major actor in intestinal inflammation. Gut 57: 1222-1229.
23. Iwasaki A, Medzhitov R, (2004). Toll-like receptor control of the adaptive immune responses. Nat Immunol 5: 987-995.
24. Janeway CA Jr, Medzhitov R, (2002). Innate immune recognition. Annu Rev Immunol 20: 197-216.
25. Kagota S, Chia E, McGuire JJ, (2011). Preserved arterial vasodilatation via endothelial protease-activated receptor-2 in obese type 2 diabetic mice. Br J Pharmacol 164: 358-371.
26. Kida Y, Inoue H, Shimizu T, Kuwano K, (2007). Serratia marcescens serralysin induces inflammatory responses through protease-activated receptor 2. Infect Immun 75: 164-174.
27. Kida Y, Higashimoto Y, Inoue H, Shimizu T, Kuwano K, (2008). A novel secreted protease from pseudomonas aeruginosa activates NF-kappa B through protease-activated receptors. Cell Microbiol 10: 1491-1504.
28. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
29. Livak KJ, Schmittgen TD, (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-4088.
30. Lolis E, Bucala R, (2003). Therapeutic approaches to innate immunity: severe sepsis and septic shock. Nat Rev Drug Discov 2: 635-645.
31. Lubbad A, Oriowo MA, Khan I, (2009). Curcumin attenuates inflammation through inhibition of TLR-4 receptor in experimental colitis. Mol Cell Biochem 322: 127-135.
32. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R, (2001). Proteinase activated receptors. Pharmacol Rev 53: 245-282.
33. McGrath J, Drummond G, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
34. Mitchell JA, Paul-Clark MJ, Clarke GW, McMaster S, Cartwright N, (2007). Critical role of Toll-like receptors and nucleotide oligomerization domain in the regulation of health and disease. J Endocrinol 53: 245-282.
35. Molino M, Barnathan ES, Numerof R, Clark J, Dreyer M, Cumashi A, et al,. (1997). Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem 272: 4043-4049.
36. Morello S, Vellecco V, Roviezzo F, Maffia P, Cuzzocrea S, Cirino G, et al,. (2005). A protective role for proteinase activated receptor 2 in airways of lipopolysaccharide-treated rats. Biochem Pharmacol 71: 223-230.
37. Moretti S, Bellocchio S, Bonifazi P, Bozza S, Zelante T, Bistoni F, et al,. (2008). The contribution of PARs to inflammation and immunity to fungi. Mucosal Immunol 1: 156-168.
38. Nakamura N, Yoshida M, Umeda M, Huang Y, Kitajima S, Inoue Y, et al,. (2008). Extended exposure of lipopolysaccharide fraction from Porphyromonas gingivalis facilitates mononuclear cell adhesion to vascular endothelium via toll-like receptor-2 dependent mechanism. Atherosclerosis 196: 59-67.
39. Nystedt S, Emilsson K, Wahlestedt C, Sundelin J, (1994). Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci U S A 91: 9208-9212.
40. Nystedt S, Ramakrishnan V, Sundelin J, (1996). The proteinase-activated receptor 2 is induced by inflammatory mediators in human endothelial cells. Comparison with the thrombin receptor. J Biol Chem 271: 14910-14915.
41. O'Neill LA, Bowie AG, (2007). The family of five: TIR-domain-containing adaptors in toll-like receptor signalling. Nat Rev Immunol 7: 353-364.
42. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al,. (1998). Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282: 2085-2088.
43. Poltorak A, Smirnova I, Clisch R, Beutler B, (2000). Limits of a deletion spanning Tlr4 in C57BL/10ScCr mice. J Endotoxin Res 6: 51-56.
44. Rallabhandi P, Nhu QM, Toshchakov VY, Piao W, Medvedev AE, Hollenberg MD, et al,. (2008). Analysis of proteinase-activated receptor 2 and TLR4 signal transduction. J Biol Chem 283: 24314-24325.
45. Roach JC, Glusman G, Rowen L, Kaur A, Purcell MK, Smith KD, et al,. (2005). The evolution of vertebrate Toll-like receptors. Proc Natl Acad Sci U S A 102: 9577-9582.
46. Roviezzo F, Bucci M, Brancaleone V, Di Lorenzo A, Geppetti P, Farneti S, et al,. (2005). Proteinase-activated receptor-2 mediates arterial vasodilation in diabetes. Arterioscler Thromb Vasc Biol 25: 2349-2354.
47. Silan C, (2008). The effect ofchronic resveratrol treatment on vascular responsiveness of streptozotocin-induced diabetic rats. Biol Pharm Bull 31: 897-902.
48. Son YH, Jeong YT, Lee KA, Choi KH, Kim SM, Rhim BY, et al,. (2008). Roles of MAPK and NF-kappaB in interleukin-6 induction by lipopolysaccharide in vascular smooth muscle cells. J Cardiovasc Pharmacol 51: 71-77.
49. Uehara A, Hirabayashi Y, Takada H, (2008). Antibodies to proteinase 3 prime human oral, lung, and kidney epithelial cells to secrete proinflammatory cytokines upon stimulation with agonists to various Toll-like receptors, NOD1, and NOD2. Clin Vaccine Immunol 15: 1060-1066.
50. Youn HS, Lee JY, Fitzgerald KA, Young HA, Akira S, Hwang DH, (2005). Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex. J Immunol 175: 3339-3346.
51. Youn HS, Saitoh SI, Miyake K, Hwang DH, (2006). Inhibition of homodimerization of Toll-like receptor 4 by curcumin. Biochem Pharmacol 72: 62-69.
52. Zhang Z, Schluesener HJ, (2006). Mammalian toll-like receptors: from endogenous ligands to tissue regeneration. Cell Mol Life Sci 63: 2901-2907.